Skip to main content
. Author manuscript; available in PMC: 2011 Mar 30.
Published in final edited form as: Nature. 2010 Sep 30;467(7315):596–599. doi: 10.1038/nature09454

Fig 4. Representative PET scans for patients taken pre-dose and following 2 weeks of dosing with PLX4032.

Fig 4

Each of these image pairs demonstrates significant reduction in FDG uptake following PLX4032 treatment. Note that tumor regressions were later documented for each of these patients: best responses were 70% for patient 45, 70% for patient 59, 68% for patient 61 and 37% for patient 69.